The Manufacturers Life Insurance Company Takes Position in Alumis Inc. $ALMS

The Manufacturers Life Insurance Company acquired a new position in shares of Alumis Inc. (NASDAQ:ALMS) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 100,215 shares of the company’s stock, valued at approximately $2,820,000.

A number of other large investors also recently modified their holdings of ALMS. Ieq Capital LLC increased its position in shares of Alumis by 4.1% in the 4th quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock valued at $170,000 after purchasing an additional 690 shares during the last quarter. Strs Ohio grew its stake in shares of Alumis by 300.0% during the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $44,000 after purchasing an additional 1,500 shares in the last quarter. ProShare Advisors LLC increased its holdings in Alumis by 12.4% in the fourth quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock valued at $143,000 after buying an additional 1,618 shares during the last quarter. KBC Group NV acquired a new stake in Alumis in the first quarter valued at $42,000. Finally, State of Wyoming purchased a new stake in Alumis during the 1st quarter worth about $57,000.

Alumis Price Performance

NASDAQ ALMS opened at $9.47 on Wednesday. The company has a fifty day moving average of $26.20 and a two-hundred day moving average of $24.93. The company has a market capitalization of $1.23 billion, a PE ratio of -2.45 and a beta of -0.80. Alumis Inc. has a 1 year low of $3.76 and a 1 year high of $31.35.

Alumis (NASDAQ:ALMS) last posted its earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.34). The firm had revenue of $1.66 million during the quarter, compared to analysts’ expectations of $3.65 million. Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. On average, research analysts expect that Alumis Inc. will post -2.95 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Jorn Drappa sold 2,447 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $64,527.39. Following the completion of the sale, the insider directly owned 56,892 shares of the company’s stock, valued at approximately $1,500,242.04. This represents a 4.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Sanam Pangali sold 1,364 shares of Alumis stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $35,968.68. Following the completion of the transaction, the insider directly owned 9,747 shares in the company, valued at $257,028.39. The trade was a 12.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 19,953 shares of company stock valued at $534,311 in the last 90 days. Company insiders own 33.70% of the company’s stock.

Trending Headlines about Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Alumis said patients with high interferon gene signature (IFNGS-high) showed robust responses, supporting plans to evaluate envudeucitinib in a smaller, biomarker-selected lupus population and potentially advance it into Phase 3. Alumis eyes late-stage lupus study despite trial miss
• Positive Sentiment: The company reported that envudeucitinib was generally well tolerated, with no new safety signals, reducing concerns that safety could prevent further development. Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in SLE
• Positive Sentiment: Alumis remains on track to submit a U.S. marketing application for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026. That program remains the company’s main near-term commercial catalyst. Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside
• Neutral Sentiment: Alumis discussed pharmacodynamic results suggesting activity in interferon-driven immune diseases, but the company is still a late-stage biotech without a commercial product, leaving valuation highly dependent on clinical and regulatory execution.
• Negative Sentiment: The LUMUS trial failed to meet both its primary and secondary endpoints in the overall SLE population. The broad lupus indication therefore appears less certain, prompting a more selective development approach. Alumis Phase 2b LUMUS Trial Misses Endpoints
• Negative Sentiment: The trial miss triggered an unusually large increase in put-option activity—4,619 puts versus typical volume of about 907—signaling heightened bearish positioning and volatility.

Analyst Ratings Changes

ALMS has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. Morgan Stanley reissued an “overweight” rating and set a $39.00 target price on shares of Alumis in a research report on Friday, May 15th. HC Wainwright restated a “neutral” rating and set a $25.00 target price on shares of Alumis in a research note on Friday, August 14th. Guggenheim upped their price target on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, May 15th. Finally, Chardan Capital increased their price target on shares of Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, May 19th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $36.73.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.